Elamipretide

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 187 publications

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.

Journal: Circulation. Heart failure
Published: June 15, 2026

Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?

Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?

Journal: Cell metabolism
Published: April 18, 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Journal: Sports medicine (Auckland, N.Z.)
Published: March 24, 2026

Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies.

Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies.

Journal: International journal of molecular sciences
Published: March 24, 2026

Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury.

Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury.

Journal: Neurochemistry international
Published: February 26, 2026

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Journal: International journal of molecular sciences
Published: February 25, 2026

Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide to emerging strategies.

Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide to emerging strategies.

Journal: Frontiers in physiology
Published: February 19, 2026

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

Journal: American journal of physiology. Heart and circulatory physiology
Published: February 19, 2026

Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.

Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.

Journal: JSES international
Published: January 19, 2026

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Journal: Lung
Published: January 13, 2026

2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.

2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 12, 2026

Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.

Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.

Journal: Tissue & cell
Published: January 03, 2026
Showing 1-12 of 187

Last Updated: 06/30/2026